KBC Group NV Acquires 51,561 Shares of Colgate-Palmolive (CL)
KBC Group NV lifted its holdings in Colgate-Palmolive (NYSE:CL) by 35.4% in the 3rd quarter, HoldingsChannel reports. The fund owned 197,104 shares of the company’s stock after buying an additional 51,561 shares during the quarter. KBC Group NV’s holdings in Colgate-Palmolive were worth $14,360,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in CL. Jacobi Capital Management LLC grew its holdings in Colgate-Palmolive by 125.5% during the 3rd quarter. Jacobi Capital Management LLC now owns 1,443 shares of the company’s stock valued at $104,000 after purchasing an additional 803 shares in the last quarter. Krilogy Financial LLC grew its holdings in Colgate-Palmolive by 23.0% during the 2nd quarter. Krilogy Financial LLC now owns 1,547 shares of the company’s stock valued at $115,000 after purchasing an additional 289 shares in the last quarter. Hanson & Doremus Investment Management grew its holdings in Colgate-Palmolive by 4.5% during the 2nd quarter. Hanson & Doremus Investment Management now owns 1,630 shares of the company’s stock valued at $121,000 after purchasing an additional 70 shares in the last quarter. Captrust Financial Advisors acquired a new stake in Colgate-Palmolive during the 2nd quarter valued at $122,000. Finally, AlphaMark Advisors LLC grew its holdings in Colgate-Palmolive by 1.5% during the 2nd quarter. AlphaMark Advisors LLC now owns 1,698 shares of the company’s stock valued at $126,000 after purchasing an additional 25 shares in the last quarter. 72.83% of the stock is owned by institutional investors.
Colgate-Palmolive (NYSE CL) opened at $74.62 on Friday. The firm has a market cap of $65,524.20, a price-to-earnings ratio of 26.00, a price-to-earnings-growth ratio of 3.15 and a beta of 0.80. The company has a current ratio of 1.23, a quick ratio of 0.92 and a debt-to-equity ratio of 24.42. Colgate-Palmolive has a fifty-two week low of $63.43 and a fifty-two week high of $77.27.
Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings data on Friday, October 27th. The company reported $0.73 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.73. The company had revenue of $3.97 billion during the quarter, compared to analyst estimates of $3.94 billion. Colgate-Palmolive had a net margin of 15.10% and a return on equity of 2,782.56%. The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period last year, the business earned $0.73 EPS. sell-side analysts predict that Colgate-Palmolive will post 2.88 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Tuesday, January 23rd will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.14%. Colgate-Palmolive’s dividend payout ratio is currently 61.78%.
In other news, CMO Mukul Deoras sold 7,500 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $73.28, for a total value of $549,600.00. Following the transaction, the chief marketing officer now directly owns 45,217 shares in the company, valued at approximately $3,313,501.76. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Justin Skala sold 126,393 shares of the firm’s stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $72.97, for a total transaction of $9,222,897.21. Following the completion of the transaction, the chief operating officer now owns 262,361 shares in the company, valued at $19,144,482.17. The disclosure for this sale can be found here. Over the last three months, insiders have sold 181,950 shares of company stock valued at $13,237,385. 1.02% of the stock is owned by company insiders.
A number of equities research analysts recently weighed in on CL shares. Citigroup lowered their price target on shares of Colgate-Palmolive from $76.00 to $75.00 and set a “neutral” rating for the company in a report on Thursday, November 2nd. Zacks Investment Research raised shares of Colgate-Palmolive from a “hold” rating to a “buy” rating and set a $81.00 price target for the company in a report on Monday, October 23rd. KeyCorp reaffirmed a “hold” rating on shares of Colgate-Palmolive in a report on Saturday, November 25th. Macquarie raised shares of Colgate-Palmolive from a “neutral” rating to an “outperform” rating and set a $81.00 price target for the company in a report on Tuesday, December 19th. Finally, SunTrust Banks raised shares of Colgate-Palmolive from a “hold” rating to a “buy” rating and raised their price target for the company from $65.00 to $85.00 in a report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $76.51.
Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with Analyst Ratings Network's FREE daily email newsletter.